Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02

NCT05205200 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

338

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Metastatic Cancer

Interventions

DRUG: SHR-1316
DRUG: SHR6390
DRUG: Nab paclitaxel
DRUG: SERD
DRUG: AI

Sponsor

Fudan University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]